Document is current
Any future updates will be listed below
-
Authors
Silva, Ananília
Haghshenas, Sadegheh
van der Laan, Liselot https://orcid.org/0000-0002-7800-8665
Levy, Michael A.
Relator, Raissa
McConkey, Haley
Kerkhof, Jennifer https://orcid.org/0000-0003-1245-6606
Skinner, Steve A.
Faivre, Laurence https://orcid.org/0000-0001-9770-444X
Lespinasse, James
Vitobello, Antonio https://orcid.org/0000-0003-3717-8374
Valenzuela, Irene
Scheffer, Ingrid E.
Russ-Hall, Sophie J.
Myers, Kenneth A. https://orcid.org/0000-0001-7831-4593
Tedder, Matthew L. https://orcid.org/0000-0003-0613-6702
Sadikovic, Bekim https://orcid.org/0000-0001-6363-0016
Cooley Coleman, Jessica A. https://orcid.org/0000-0002-7050-8796
-
Funding
Funding for this research was provided by:
Government of Canada through Genome Canada and the Ontario Genomics Institute - OGI-188
- License Information
-
More Information
Article History
Received: 25 March 2025
Revised: 2 October 2025
Accepted: 7 November 2025
First Online: 25 November 2025
Competing interests
: BS is a shareholder in EpiSign Inc involved in commercial applications of EpiSign™ technology.
: All samples and data records were anonymized to protect the identities of the individuals involved. The research protocol received ethical approval from the Research Ethics Board (REB 106302) at Western University and the Institutional Review Board (IRB) of Self Regional Healthcare. Informed consent was obtained from physicians for the utilization of clinical information pertaining to the described patients.
